Latest news
H3 Pharma receives approvable letter from FDA for Sanvar® for esophageal variceal bleeding
Debiopharm S.A. and Rowfarma S. de R.L. de C.V. enter into an Exclusive Licensing Agreement in Mexico for two approved…
Debiopharm S.A. and GPC Biotech AG Announce Partnering of Small Molecule MHC Class II Antagonists Program for Autoimune Diseases
Debiopharm S.A. and Tulane Cancer Center nominate Dr T. Curiel and Dr W. Zou, the 2004 Mauvernay Research Excellences Scholars
New Data presented on Debiopharm´s Debio-025 at the 11th International Symposium on Hepatits C virus and related viruses
Debiopharm and Watson Pharmaceuticals enter into an Exclusive Licensing Agreement for two approved urology products – Trelstar® DEPOT and Trelstar®…
H3 Pharma Inc. and DSM Biologics sign development agreement for SC-1 monoclonal antibody for the treatment of gastric cancer
Mexico becomes first country to approve H3 Pharma´s Sanvar® for esophageal variecal bleeding and four other indications
Debiopharm´s Eloxatin® (Oxaliplatin) awarded Prix Galien in France for innovative cancer therapy
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.